Print

Accelovance Grows Revenues and Executive Team  
7/14/2008 12:45:12 PM

July 11, 2008 – Rockville, Maryland

Accelovance, a leader in CRO services for vaccine clinical research, continues to demonstrate its value to the industry as revenues grow and the company expands its executive team to include another industry veteran. Over the past six months, Accelovance revenues are up over 40% largely due to strong vaccine trial performances and its ability to conduct high quality, cost effective studies within reduced timelines.

“It is encouraging to see our controlled process of using Accelovance high throughput sites and experienced vaccine CRO team deliver for our clients. Our mission is to provide exceptional value to our sponsors. We are pleased with our progress and significant revenue growth in the first half of 2008,” commented Accelovance President and CEO, Stephen J. Trevisan.

Accelovance has also recently welcomed Lisa Hanges to its management team in the role of Senior Vice President. Ms. Hanges has been in the industry nearly 20 years, having held similar senior management positions at other CROs including Cetero Research, Quintiles, and Nexigent (Covance). Additionally, Ms. Hanges co-founded ePharmaSolutions in 2001 and is a frequent speaker on clinical trials technology, research and strategic partnerships. Her experience adds to Accelovance’s leadership team that includes individuals with CRO, large pharma and biotech backgrounds.

“It is exciting to join a company emerging as a leader in vaccine clinical research. The Accelovance team has accomplished a lot in a relatively short amount of time and I look forward to serving our clients and contributing to the company expansion in my new role,” said Ms. Hanges.

Headquartered in Rockville, Maryland, Accelovance is a privately held company with a clinical services focus on vaccine research. It has developed a unique operational system that optimizes the quality and productivity of multiple clinical sites through strong central management and targeted pro-active patient recruitment. A flexible service offering gives clients a cost-effective solution that delivers reduced enrollment timelines, higher retention rates, and quality study execution. In China, the Company operates through its wholly-owned foreign enterprise in Beijing as a contract research organization (CRO). Delivering high quality and timely clinical development services, Accelovance is committed to understanding and meeting its clients needs to contribute to their successes.

CONTACT: Media: Garrett D. Smith at 240.238.4900


//-->